Pretransplant systemic inflammation and acute rejection after renal transplantation

Transplantation

Volumn 69, Issue 5, 2000, Pages 869-874

  Perez, Richard V ^a   Brown, David J ^a   Katznelson, Steven A ^a,b   Dubin, Joel A ^c   Müller, Hans Georg ^c   Chang, Tammy ^a,d   Rudich, Steven M ^a   McVicar, John P ^a   Kaysen, George A ^a,b,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Med Intelligence   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GRAFT REJECTION; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; KIDNEY TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RISK FACTOR;

EID: 0034654114     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200003150-00034     Document Type: Article

References (32)

1. Liuzzo G, Biasucci L, Gallimore J, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994; 331: 417.
2. Alexander RW. Inflammation and coronary artery disease. N Engl J Med 1994; 331: 468.
3. Haverkate F, Thompson S, Pyke S, Gallimore J, Pepys M, for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997; 1: 462.
4. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973.
5. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998; 97: 425.
6. Kaysen GA, Stevenson FT, Depner TA. Determinants of albumin concentration in hemodialysis patients. Am J Kidney Dis 1997; 29: 658.
7. Owen FO, Lowrie EG. C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int 1998; 54: 627.
8. Bergstrom J, Heimburger O, Lindhollm B, Qureshi AR. Elevated serum CRP is a strong predictor of increased mortality and low serum albumin in hemodialysis (HD) patients. J Am Soc Nephrol 1995; 6: 573.
9. White JE, Meyer E, Hardy MA. Prediction of onset and termination of renal allograft rejection by serum levels of C-reactive protein. Transplant Proc 1981; 13: 682.
10. Rowe IR, Magoha GA, Malik FE, Whitwam JG, Williams G, Pepys MB. Measurement of serum C-reactive protein concentration after renal transplantation. Nephrol Dial Transplant 1987; 2: 39.
11. Dyck RF. C-reactive protein: a better indicator of complications other than acute rejection in renal allograft recipients? Clin Biochem 1988; 21: 359.
12. Lalla MLT, Eklund B, Ahonen J The clinical significance of serum C-reactive protein after renal transplantation. Transplant Proc 1988; 20: 402.
13. Harris KR, Digard NJ, Lee HA. Serum C-reactive protein: a useful and economical marker of immune activation in renal transplantation. Transplantation 1996; 61: 1593.
14. Steinhoff J, Einecke G, Niederstadt C, et al. Renal graft rejection or urinary tract infection? The value of myeloperoxidase, C-reactive protein, and α2-macroglobulin in the urine. Transplantation 1997; 64: 443.
15. Casi MT, Bulatovic G, Orlic P, Sabljar-Matovinovic M. The diagnostic capacity of serum amyloid A protein for early recognition of kidney allograft rejection. Nephrol Dial Transplant 1995; 10: 1901.
16. Hartman A, Eide TC, Fauchald P, et al. Serum amyloid A protein is a clinically useful indicator of acute renal allograft rejection. Nephrol Dial Transplant 1997; 12: 161.
17. Casals C, Varela A, Ruano M, et al. Increase of C-reactive protein and decrease of surfactant protein A in surfactant after lung transplantation. Am J Respir Crit Care Med 1998; 157: 43.
18. Pirsch J, Miller J, Deierhoi M, Vicenti F, Filo R, and the FK506 Kidney Transplant Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997; 63: 977.
19. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 1: 1321.
20. Vicenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with Daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998; 338: 161.
21. Castell JV, Gomez-Lechon M, David M, et al. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. Febs Lett 1989; 242: 237.
22. Bataille R, Klein B. C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo. Arthritis Rheum 1992; 35: 982.
23. Vetter ML, Gewurz H, Hansen B, James K, Baum L. Effects of C-reactive protein on human lymphocyte responsiveness. J Immunol 1983; 130: 2121.
24. Baum L, Johnson B, Berman S, Graham D, Mold C. C-reactive protein is involved in natural killer cell-mediated lysis but does not mediate effector-target cell recognition. Immunology 1987; 61: 93.
25. Ballou S, Kushner I. C-reactive protein and the acute phase response. Adv Intern Med 1992; 37: 313.
26. Bout D, Pontet M, Vorng H, Deslee D, Capron A. Rat resistance to schistosomiasis: Platelet-mediated cytotoxicity induced by C-reactive protein. Science 1986; 231: 153.
27. Pue C, Mortensen R, Marsh C, Pope H, Wewers M. Acute phase levels of C-reactive protein enhance IL-1β and IL-1rα production by human blood monocytes but inhibit IL-1β and IL-1rα production by alveolar macrophages. J Immunol 1996; 156: 1594.
28. Vigo C. Effect of C-reactive protein on platelet-activating factor-induced platelet aggregation and membrane stabilization. J Biol Chem 1985; 260: 3418.
29. Wolbink G, Brouwer M, Buysmann S, ten Berge I, Hack CE. CRP-mediated activation of complement in vivo. J Immunol 1996; 157: 473.
30. Honkanen E, Gronhagen-Riska C, Teppo A, Maury C, Meri S. Acute-phase proteins during hemodialysis : Correlations with serum interleukin-1 beta levels and different dialysis membranes. Nephron 1991; 57: 283.
31. Reinke P, Fietze E, Ode-Hakim S, et al. Late-acute allograft rejection and symptomless cytomegalovirus infection. Lancet 1994; 1: 1737.
32. Ayus J, Sheikh-Hamad D. Silent infection in clotted hemodialysis access grafts. J Am Soc Nephrol 1998; 9: 1314.